Journal of Medicinal Chemistry · 2009 · 53 citations · 26 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryStructure-activity RelationshipsVirologyAntiretroviral TherapyAntiviral AgentsAntiviral PharmacologyAntiviral TherapyEnzyme InhibitionAntiviral Drug DesignAntiviral Drug MechanismsAntiviral Structure-activity RelationshipsAntiviral TherapeuticsCell-based AssaysCell-based Screening AssaysChemical Structure-activity Relationships
HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication. Recently, HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Herein, we report the discovery of azaindole carboxylic acids and azaindole hydroxamic acids as potent inhibitors of the HIV-1 IN enzyme and their structure-activity relationships. Several 4-fluorobenzyl substituted azaindole hydroxamic acids showed potent antiviral activities in cell-based assays and offered a structurally simple scaffold for the development of novel HIV-1 IN inhibitors.
26
Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations
The maximal affinity of ligands
Irwin D. Kuntz, K. Chen, Kim A. Sharp et al. · Proceedings of the National Academy of Sciences · 1999 · 845 citations
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Roy M. Gulick, Jacob Lalezari, James Goodrich et al. · New England Journal of Medicine · 2008 · 741 citations · Full text
O. S. Weislow, Rebecca Kiser, Donald L. Fine et al. · JNCI Journal of the National Cancer Institute · 1989 · 691 citations